Cytogenetic effects of 1-p-(3-methyltriazeno)benzoic acid potassium salt on human lymphocytes in vitro

P. Vernole, D. Caporossi, B. Tedeschi, B. Porfirio, G. Melino, E. Bonmassar, B. Nicoletti

Research output: Contribution to journalArticle

Abstract

The triazene derivative 1-p-(3-methyltriazeno)benzoic acid potassium salt (MTBA) shows pharmacological properties similar to those of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC, trade name dacarbazine), which is known to induce antigenic modulation in tumor cells (xenogenization) and is currently used in cancer therapy. Mutagenic, teratogenic and cancerogenic properties of triazene derivatives have been demonstrated but there is no report on their possible clastogenicity. We describe here the in vitro cytogenetic effects of MTBA on human peripheral blood lymphocytes. The drug was tested at different culture times in a range of concentrations from 2 to 500 μg/ml. MTBA caused a dose-dependent increase in the frequency of chromosomal breaks. Different blood donors showed different sensitivity to the treatment. Cell proliferation, as evaluated by [3H]thymidine incorporation, was inhibited at the highest concentrations of the drug. These data might be relevant for comparison with in vivo effects of the drug in clinical trials and to investigate the possible relations between xenogenization induced by MTBA and its genetic and cytogenetic effects in human lymphocytes.

Original languageEnglish
Pages (from-to)349-356
Number of pages8
JournalMutation Research/Genetic Toxicology
Volume189
Issue number3
DOIs
Publication statusPublished - 1987

Fingerprint

Lymphocytes
Cytogenetics
Dacarbazine
Triazenes
Antigenic Modulation
Blood
Pharmaceutical Preparations
Derivatives
Chromosome Breakage
Trademarks
Cell proliferation
Blood Donors
Cell culture
Thymidine
Names
Tumors
Neoplasms
Cells
Cell Proliferation
Modulation

Keywords

  • (Human lymphocytes in vitro)
  • 1-p-(3-Methyltriazeno)benzoic acid potassium salt
  • Triazene derivatives
  • Xenogenization

ASJC Scopus subject areas

  • Genetics
  • Toxicology
  • Medicine(all)

Cite this

Cytogenetic effects of 1-p-(3-methyltriazeno)benzoic acid potassium salt on human lymphocytes in vitro. / Vernole, P.; Caporossi, D.; Tedeschi, B.; Porfirio, B.; Melino, G.; Bonmassar, E.; Nicoletti, B.

In: Mutation Research/Genetic Toxicology, Vol. 189, No. 3, 1987, p. 349-356.

Research output: Contribution to journalArticle

Vernole, P. ; Caporossi, D. ; Tedeschi, B. ; Porfirio, B. ; Melino, G. ; Bonmassar, E. ; Nicoletti, B. / Cytogenetic effects of 1-p-(3-methyltriazeno)benzoic acid potassium salt on human lymphocytes in vitro. In: Mutation Research/Genetic Toxicology. 1987 ; Vol. 189, No. 3. pp. 349-356.
@article{b5ac51c5c3a645f5b30012d061d7cac2,
title = "Cytogenetic effects of 1-p-(3-methyltriazeno)benzoic acid potassium salt on human lymphocytes in vitro",
abstract = "The triazene derivative 1-p-(3-methyltriazeno)benzoic acid potassium salt (MTBA) shows pharmacological properties similar to those of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC, trade name dacarbazine), which is known to induce antigenic modulation in tumor cells (xenogenization) and is currently used in cancer therapy. Mutagenic, teratogenic and cancerogenic properties of triazene derivatives have been demonstrated but there is no report on their possible clastogenicity. We describe here the in vitro cytogenetic effects of MTBA on human peripheral blood lymphocytes. The drug was tested at different culture times in a range of concentrations from 2 to 500 μg/ml. MTBA caused a dose-dependent increase in the frequency of chromosomal breaks. Different blood donors showed different sensitivity to the treatment. Cell proliferation, as evaluated by [3H]thymidine incorporation, was inhibited at the highest concentrations of the drug. These data might be relevant for comparison with in vivo effects of the drug in clinical trials and to investigate the possible relations between xenogenization induced by MTBA and its genetic and cytogenetic effects in human lymphocytes.",
keywords = "(Human lymphocytes in vitro), 1-p-(3-Methyltriazeno)benzoic acid potassium salt, Triazene derivatives, Xenogenization",
author = "P. Vernole and D. Caporossi and B. Tedeschi and B. Porfirio and G. Melino and E. Bonmassar and B. Nicoletti",
year = "1987",
doi = "10.1016/0165-1218(87)90067-X",
language = "English",
volume = "189",
pages = "349--356",
journal = "Mutation Research - Genetic Toxicology Testing and Biomonitoring of Environmental or Occupational Exposure",
issn = "0165-1218",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Cytogenetic effects of 1-p-(3-methyltriazeno)benzoic acid potassium salt on human lymphocytes in vitro

AU - Vernole, P.

AU - Caporossi, D.

AU - Tedeschi, B.

AU - Porfirio, B.

AU - Melino, G.

AU - Bonmassar, E.

AU - Nicoletti, B.

PY - 1987

Y1 - 1987

N2 - The triazene derivative 1-p-(3-methyltriazeno)benzoic acid potassium salt (MTBA) shows pharmacological properties similar to those of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC, trade name dacarbazine), which is known to induce antigenic modulation in tumor cells (xenogenization) and is currently used in cancer therapy. Mutagenic, teratogenic and cancerogenic properties of triazene derivatives have been demonstrated but there is no report on their possible clastogenicity. We describe here the in vitro cytogenetic effects of MTBA on human peripheral blood lymphocytes. The drug was tested at different culture times in a range of concentrations from 2 to 500 μg/ml. MTBA caused a dose-dependent increase in the frequency of chromosomal breaks. Different blood donors showed different sensitivity to the treatment. Cell proliferation, as evaluated by [3H]thymidine incorporation, was inhibited at the highest concentrations of the drug. These data might be relevant for comparison with in vivo effects of the drug in clinical trials and to investigate the possible relations between xenogenization induced by MTBA and its genetic and cytogenetic effects in human lymphocytes.

AB - The triazene derivative 1-p-(3-methyltriazeno)benzoic acid potassium salt (MTBA) shows pharmacological properties similar to those of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC, trade name dacarbazine), which is known to induce antigenic modulation in tumor cells (xenogenization) and is currently used in cancer therapy. Mutagenic, teratogenic and cancerogenic properties of triazene derivatives have been demonstrated but there is no report on their possible clastogenicity. We describe here the in vitro cytogenetic effects of MTBA on human peripheral blood lymphocytes. The drug was tested at different culture times in a range of concentrations from 2 to 500 μg/ml. MTBA caused a dose-dependent increase in the frequency of chromosomal breaks. Different blood donors showed different sensitivity to the treatment. Cell proliferation, as evaluated by [3H]thymidine incorporation, was inhibited at the highest concentrations of the drug. These data might be relevant for comparison with in vivo effects of the drug in clinical trials and to investigate the possible relations between xenogenization induced by MTBA and its genetic and cytogenetic effects in human lymphocytes.

KW - (Human lymphocytes in vitro)

KW - 1-p-(3-Methyltriazeno)benzoic acid potassium salt

KW - Triazene derivatives

KW - Xenogenization

UR - http://www.scopus.com/inward/record.url?scp=0023627953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023627953&partnerID=8YFLogxK

U2 - 10.1016/0165-1218(87)90067-X

DO - 10.1016/0165-1218(87)90067-X

M3 - Article

C2 - 3670338

AN - SCOPUS:0023627953

VL - 189

SP - 349

EP - 356

JO - Mutation Research - Genetic Toxicology Testing and Biomonitoring of Environmental or Occupational Exposure

JF - Mutation Research - Genetic Toxicology Testing and Biomonitoring of Environmental or Occupational Exposure

SN - 0165-1218

IS - 3

ER -